Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.

@article{Gyanchandani2013Interleukin8AA,
  title={Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.},
  author={Rekha Gyanchandani and D. M. C. Sano and Marcus V Ortega Alves and Jonah D. Klein and Beth A. Knapick and Sanders Oh and Jeffrey N. Myers and Seungwon W Kim},
  journal={Oral oncology},
  year={2013},
  volume={49 8},
  pages={761-70}
}
OBJECTIVES Bevacizumab, a monoclonal antibody to VEGF-A, is under active clinical evaluation in head and neck squamous cell carcinoma (HNSCC) and appears to be a promising therapy in at least a subset of patients. However, there are no reliable predictive biomarkers to identify those patients most likely to benefit. In this study, we assessed the efficacy of bevacizumab in HNSCC xenograft models to characterize escape mechanisms underlying intrinsic resistance and identify potential biomarkers… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…